EGFR and pancreatic neoplasm: Though many clinical trials had been conducted to ascertain the optimum therapy utilizing gemcitabine in combination with multiple chemotherapeutic agents such as 5-FU, capecitabine, pemetrexed, topoisomerase inhibitors, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, erlotinib, bevacizumab, irinotecan, exatecan, platinum compounds (cisplatin and oxaliplatin), and taxanes (paclitaxel and docetaxel), almost none of them was proven to be more effective, in comparison with gemcitabine as a single agent for treating pancreatic cancer [8].